---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027935"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:14:26.361038+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics Q2 net loss $35.9M; cash $286.7M; signs CFT8919 license deal with Betta

## Summary
- Net loss $35.9M ($0.73 per share) vs $27.4M ($0.56) in Q2 2022; revenue fell to $2.7M from $13.8M.
- Cash, equivalents and marketable securities $286.7M as of June 30, expected to fund ops into 2H 2025.
- Exclusive license for CFT8919 (EGFR L858R degrader) with Betta Pharma in Greater China: $10M upfront, $25M equity investment, up to $357M milestones plus royalties.
- U.S. IND cleared for CFT8919; Phase 1/2 trials for CFT7455, CFT8634, CFT1946 ongoing; Phase 1 dose escalation data expected 2H 2023.
- Appointed Len Reyno as CMO and Mary Christian as SVP Regulatory in July 2023.

## SEC filing metadata
- accession: 0001628280-23-027935
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/0001628280-23-027935-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/cccc-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027935
- JSON: https://secwatch.observer/filing/0001628280-23-027935.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027935.txt

## Key facts
- Earnings Releases
  C4 Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $2.7 million.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $2.7 million
  - Result: reported results
  source text: for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023. SECOND QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. The decrease in revenue was due to a reduction of revenue recognized for research activities under the Biogen and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023027935/0001628280-23-027935-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.